Gilead enters deal with Carna Biosciences to develop small-molecule drugs in immuno-oncology

Gilead Sciences entered a collaboration with Carna Biosciences to develop and commercialise small-molecule compounds in immuno-oncology, the companies announced. Under the agreed terms, Gilead will make an upfront payment of $20 million, with Carna eligible to receive up to $450 million in further milestone payments and royalties on future net sales.

The drugmakers noted that as part of the deal, Gilead will license global rights from Carna to develop and commercialise inhibitors against an undisclosed immuno-oncology target. In addition, Gilead will also have exclusive access to Carna's lipid kinase drug discovery platform.

Commenting on the agreement, Gilead's head of R&D John McHutchison said the company "is committed to building a pipeline in immuno-oncology with a focus on opportunities with the potential to be first-in-class or to be meaningfully differentiated from other therapeutic options." Last week, the company entered a collaboration with Nurix Therapeutics potentially worth more than $2 billion to develop a pipeline of targeted protein degradation drugs for patients with cancer and other diseases.

To read more Top Story articles, click here.